Open letter to Europe by André Rogaczewski CEO and co-founder of Netcompany: Europe must stand tall
23.4.2025 06:30:00 CEST | Business Wire | Press release
On the night of 22 April, the Statue of Liberty at Pont de Grenelle in Paris was illuminated with the message: “Stand Tall Europe”. Once a gift symbolising the transatlantic alliance and shared ideals of the West, the statue now stands as a reminder of a fellowship through centuries that is put under heavy pressure.
The following is an open letter by André Rogaczewski CEO and co-founder of Netcompany:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422921783/en/
Statue of Liberty at Pont de Grenelle last night in Paris – Iluminated with the message ”Stand Tall Europe”.
Europeans,
This is your digital awakening.
We all know that leading technologically is paramount for competitiveness and the creation of growth, prosperity, and welfare.
Europe’s digital backbone is to a large extent built on systems we don’t necessarily control. From data centers to cloud systems – in the applications and algorithms that shape our decisions.
While we rely on digital services in all our core societal areas— communication, financial services, welfare benefits, pensions, healthcare, even elections—the digital applications and infrastructures behind are too often dependent on non-European systems.
What we need is a response. To protect our individual rights, and shape a digital European ecosystem rooted in our own democratic values – not those imposed by people who no longer necessarily share our beliefs.
That’s why Netcompany launched a campaign on the night of 22 April by illuminating the Statue of Liberty in Paris with the message: “Stand Tall Europe”.
We chose the Statue of Liberty because it stands as a symbol of freedom, justice, the end of oppression, and opportunity for all. A gift from Europe to the US symbolising the values we created together and used to share. It seems now that Europe herself alone is facing the challenge of protecting those same ideals in a digital world.
Where the Statue of Liberty lifts a torch, Europe’s task today is to light the digital path forward—by asserting digital sovereignty, defending rights online, and building our own trusted secure systems and applications that our societies can rely on and prosper with.
We must embrace the digital revolution, establish more European datacenters, set up trusted age-verification systems to protect our children, and ensure our voters are not filled with digital propaganda.
We must quickly build trustworthy, robust, fair, and transparent applications and systems showing everyone else that responsible digital transformation is the way to create world-leading innovation, growth and progress.
That means offensively using AI designed with European values and transparency to create efficient European private and public administration. It means developing intelligent digital twins for our physical infrastructure across all industries to uniquely optimise European businesses. In fact, we must build world leading digital applications for Europe to become a leading region of the world.
We are calling for more European solutions—built by European companies, accountable to European citizens.
Europe’s future prosperity and growth depends on it and hence it also depends on our ability to attract, develop, and unite diverse world-class talent from everywhere.
We must make this continent the most attractive destination for the world’s sharpest minds.
This is also a call for all of you who want to contribute to the European digital awakening, wherever you are. We need you.
There’s no quick fix. But we are ready. We believe in a digital future where Europe owns more of its systems, protects its citizens, and leads with integrity.
Let’s take back the future.
Yours sincerely,
André Rogaczewski
CEO and co-founder of Netcompany
About André Rogaczewski
André Rogaczewski founded Netcompany in 2000 and has overseen its evolution into one of Europe’s fastest growing and most successful IT services companies, with a global headcount of +8,250 talented employees across +10 European countries.
With his technical background, a master's degree in computer science from Aalborg University and a true vision for society’s digital future, he has led the company through tremendous growth and built a unique delivery model unmatched elsewhere in the IT industry. André was born in Poland and grew up in Aalborg, Denmark.
About Netcompany
Founded in 2000 in Copenhagen, Denmark, Netcompany provides essential IT solutions for both societal and business needs, aiding our private and public clients in their digital evolution towards a more efficient and sustainable future.
Our team of skilled professionals drives sustainable innovation, consistently advancing and expanding our impact - one solution at a time.
By building flexible, scalable and secure digital solutions, we help Europe lead the way towards responsible digitalisation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422921783/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom